April 15, 2024 4:34pm
As cell and gene therapy sector continues roll downward
Pre-open Indicators: 3 Positive and 2 Negative Indicators
A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.
Never leave an investor uninformed! A trusted source of factual reporting!
The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!
Monday: The Dow closed DOWN -248.13 points or -0.65%, the S&P closed DOWN -61.59 points or -1.20% while the Nasdaq closed DOWN -290.08 points or -1.79%
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes and the cell and gene therapy sector retreated on Monday … as yields popped after data showed retail sales increased 0.7% in March.
- Higher rates poured cold water on the market bounce seen Monday morning.
- The yield on the closely followed 10-year Treasury rose above the key 4.6% level in the session and touched its highest point since mid-November.
Economic Data Docket: retail sales in March rose 0.7% from the prior month. The reading topped economist expectations for a rise of 0.4%, signaling consumers continued to spend despite a higher interest-rate environment.
Monday’s RegMed Investors’ (RMi) opening bell: “Any which way you can. Dangerous geo-political times as I stated Friday, “start looking for bottoms” amongst the wreckage>” … https://www.regmedinvestors.com/articles/13417
Pre-open Indicators: 3 Positive < Vericel (VCEL +$0.80), Intellia Therapeutics (NTLA -$1.35), Ultragenyx Pharmaceuticals (RARE -$4.13)> and 2 Negative Indicators < Alnylam Pharmaceuticals (ALNY -$0.80), Beam Therapeutics (BEAM -$0.23)>
Advance/Decline (A/D) Line:
- Monday’s advance/decline line at the open was negative with 8 incliner, 24 decliners and 3 flats; ending with a negative close of 3 incliners, 30 decliners and 2 flats
- Friday’s advance/decline line at the open was negative with 7 incliner, 25 decliners and 3 flats; ending with a negative close of 3 incliners, 32 decliners and 0 flats
Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:
Q2/24: 9 negative and 2 positive closes
Q1/24:
- March, 1 holiday, 8 positive and 12 negative closes
- February, 1 holiday, 9 negative and 11 positive closes
- January: 2 holiday, 12 negative and 8 positive closes
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was down -1.34% and the XBI was down -2.05%
- Friday, the IBB was down -2.08% and the XBI was down -3.43%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +1.77 point or +10.21% at 19.06
- Friday was up +2.40 points or +16.11% at 17.31
Monday’s Closing Down (10 of 30):
- Ultragenyx Pharmaceuticals (RARE -$4.13 after Friday’s -$3.70),
- Blueprint Medicine (BPMC -$2.07 after Friday’s -$5.42),
- CRISPR Therapeutics (CRSP -$1.95 after Friday’s -$2.24)
- Agenus (AGEN -$1.65),
- Intellia Therapeutics (NTLA -$1.35 after Friday’s -$0.74),
- BioLife Solutions (BLFS -$0.82),
- Alnylam Pharmaceuticals (ALNY -$0.80 after Friday’s -$3.59),
- Solid Biosciences (SLDB -$0.37),
- Prime Medicine (PRME -$0.29),
- Verve Therapeutics (VERV -$0.29),
Flat (2):
- Generation Bio (GBIO)
- Harvard Apparatus RT (OTCQB: HRGN)
Monday’s Closing Up (3 of 3):
- Vericel (VCEL +$0.80 after Friday's -$0.82),
- Sangamo Therapeutics (SGM) +$0.0017),
- Homology Medicine (FIXX +$0.0071 after Friday's +$0.0071),
Q2/24 – April
- (4/15) Monday closed negative with 3 incliners, 30 decliners and 2 flats
The BOTTOM LINE: Cell and gene therapy sector equities have sold off … yet again, as investors sharply readjusted any expectation.
- As I called it this a.m., “Any which way you can. Dangerous geo-political times as I stated Friday, “start looking for bottoms” amongst the wreckage.”
Last week, I wrote that I favor … caution over the next few weeks! Wednesday … proved me true, yet again, again and again!
The top three (3) performing in the session:
- Monday: Ultragenyx Pharmaceuticals (RARE), Blueprint Medicine (BPMC) and CRISPR Therapeutics (CRSP)
The worst three (3) in the session:
- Monday: Vericel (VCEL), Sangamo Therapeutics (SGMO) and Homology Medicine (FIXX)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
